The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
Matthew Frigault, MD, MS
Advertisement
Clinical Director, Cell and Gene Therapy Program, Mass General
Articles by Matthew Frigault, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
4
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
5
